Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company’s strong revenue and install ...
In the latest quarter, 6 analysts provided ratings for PROCEPT BioRobotics (NASDAQ:PRCT), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...
The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...
Analysts' ratings for PROCEPT BioRobotics (NASDAQ:PRCT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...
As you might know, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) just kicked off its latest first-quarter results with some very strong numbers. It looks like a positive result overall, with revenues ...
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) just released its third-quarter report and things are looking bullish. It looks like a positive result overall, with revenues of US$83m beating forecasts ...
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Total revenue for the first quarter of 2025 was $69.2 million, an increase of 55% compared to the prior year period. U.S. revenue was $60.3 million, representing growth of 50% compared to the prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback